Outlook: Aduhelm has dangerous side effects; Predatory bacteria could be the key to new antibiotics

Read recent comments on drug cost issues.

Cincinnati Enquirer: Controversial Alzheimer’s drug has inconclusive results and high cost

I agree that Alzheimer’s disease is a devastating and progressive disease. All of us, doctors and patients, are looking for an effective treatment for people with Alzheimer’s disease. However, the new drug that U.S. Representative Brad Wenstrup is referring to, called Aducanamab, or Aduhelm, from Biogen (Cambridge, Massachusetts), is not the cause of the celebration he describes (“Faulty legislation blocks the research on Alzheimer’s disease, cures them”, August 2019). 17). (David C. Fabrey, 9/2)

Scientific American: Predatory bacteria are fierce, ballistic and full of potential

In 1962, Heinz Stolp, a researcher in Berlin, was looking for new viruses when he ran out of filters that separated them from his samples. He therefore replaced the filters with slightly larger holes: 1.35 microns instead of 0.2 microns. No virus, which normally reproduces very quickly, grew on the glass plates he had covered with bacteria to use as virus food, and by then the contents should have been discarded. (Jennifer Frazer, 9/5)

New England Journal of Medicine: Intradermal Monkeypox Vaccination — Individual and Public Health Benefits

Intradermal vaccination delivers the antigen into the space between the epidermis and the dermis. This space is an anatomically favorable site for immune stimulation, enriched with a heterogeneous population of dendritic cells, macrophages and monocytes that give this tissue a potent ability to detect and respond robustly to immunological stimuli, including those present in vaccines. (John T. Brooks, MD, et al, 8/31)

The Boston Globe: What to do with opioid settlement funds? Open overdose prevention centres.

Over the past year, there have been a number of significant settlements with pharmaceutical companies, medical distributors and pharmacies to explain the harm caused by the overmarketing, distribution and prescription of opioids in late 90s and into the 2000s. (Abdullah Shihipar, Alexandra B. Collins and Brandon DL Marshall. 9/5)

New England Journal of Medicine: RETHINCking COPD — Bronchodilators for symptomatic tobacco-exposed people with preserved lung function?

Smoking is the leading cause of chronic obstructive pulmonary disease (COPD) worldwide. Worldwide, more than 1.3 billion people smoke and 384 million people have COPD.1 COPD is diagnosed clinically on the basis of persistent airflow limitation measured by spirometry in people with a history of smoking and having frequent respiratory symptoms. (Don D. Sin, MD, MPH, 9/4)

This is part of the KHN Morning Briefing, a summary of health policy coverage from major news outlets. Sign up for an email subscription.

Comments are closed.